Daily Newsletter

29 September 2023

Daily Newsletter

29 September 2023

FDA approves IDE for HYDRAFIL system in degenerative disc disease study

ReGelTec aims to start enrolment in early 2024 for the trial evaluating its disc-mimicking hydrogel injecting system.

Robert Barrie September 28 2023

The US Food and Drug Administration (FDA) has granted ReGelTec an investigational device exemption (IDE) for the company’s HYDRAFIL system.

The device contains a polymer that is injected into a diseased disc and cools to form an integrated solid. This mimics the biomechanical properties of a natural disc.

The hydrogel technology’s safety and effectiveness are being evaluated in a multicentre, single-blinded, randomised, controlled trial (NCT06011551). The study, called HYDRAFIL-D, is estimated to enrol around 225 patients with axial chronic back pain due to degenerative disc disease and who have not responded to conservative care. ReGelTec expects to begin enrolment in early 2024.

After 12 months of the gel’s implantation, ReGelTec will assess function, serious adverse events, surgical site infections, intercurrent events, and radiographic findings to determine clinical success.

The gel implant is delivered percutaneously via a needle under local anaesthesia to the affected lumbar disc.

Degenerative disc disease is considered a normal part of ageing, but its effects on motion can severely affect daily activities. Artificial discs are becoming a gold standard treatment for the condition but require invasive procedures. According to GlobalData’s medical device pipeline, 32 artificial disc replacement systems are in various stages of development. ReGelTec says its product, however, could offer a minimally invasive treatment option.

Dr Kasra Amirdelfan, director of clinical research at California’s Boomerang Healthcare, and one of two national principal investigators said: “The HYDRAFIL System is designed for a segment of the chronic low back pain population who are not very good candidates for conventional spine surgery.

"When conservative care fails, these patients have limited treatment options. HYDRAFIL appears to be a great option for these patients.”

In June, Synergy Spine Solutions completed enrolment for its IDE clinical trial evaluating its artificial disc in patients with degenerative disc disease.

Generative AI set to transform the medical devices industry

Generative AI can improve personalized healthcare by collecting data from patients via wearable devices, which can provide continuous, real-time data that can complement traditional data sources such as imaging, patient records, and more. It can also enhance existing imaging techniques by generating high-quality images of organs using data from low-resolution images (such as ultrasounds). However, the collection and use of patient healthcare data through AI medical products could conflict with regulations around the globe.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close